CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Quantrx Biomedical Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Quantrx Biomedical Corporation
P.O. Box 4960
Phone: (267) 880-1595p:267 880-1595 TUALATIN, OR  97062  United States Ticker: QTXBQTXB

Business Summary
QuantRx Biomedical Corporation has developed its patented miniform pads and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs (the OTC Business). The Company is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents (the Diagnostics Business). The Company's platforms include inSync, Unique and original equipment manufacturer (OEM) branded over-the-counter and laboratory testing products based on its core intellectual property related to the Company PAD technology. Its OTC Business includes commercialization of its InSync feminine hygienic interlabial pad, the Unique Miniform for hemorrhoid application, and other treated miniforms, as well as maintaining established and continuing licensing relationships related to the OTC Business. It also owns certain diagnostic testing technology that is based on our lateral flow patents.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202212/31/2021YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer ShalomHirschman 78 12/31/2010 9/1/2005
Director Michael S.Abrams 47 3/1/2012 3/1/2012

General Information
Outstanding Shares: 78,696,461 (As of 5/16/2022)
Shareholders: 279
Stock Exchange: OTC
Federal Tax Id: 330202574
Email Address: hjr@afem.com


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, June 27, 2022